期刊文献+

非小细胞肺癌患者的预后因素分析 被引量:6

下载PDF
导出
摘要 目的 分析非小细胞肺癌(NSCLC)患者的预后因素.方法对115例NSCLC患者进行生存分析.结果 115例NSCLC患者的1、2、3年生存率分别为38%、26%、20%.总的中位生存期为8.0个月,Cox分析显示性别、临床分期是影响NSCLC患者预后的独立因素.其中90例Ⅲb~Ⅳ期NSCLC患者的1、2、3年生存率分别为26%、13%、3%,总的中位生存期为5.0个月,Cox分析显示远处转移与否、治疗方式是影响Ⅲb~Ⅳ期NSCLC患者预后的独立因素.积极治疗者获得较长生存期(中位生存期9.0个月),长于对症支持治疗者(中位生存期3.0个月),差异有统计学意义(P=0.003).结论 性别、临床分期、远处转移与否是影响NSCLC患者预后的重要因素,早发现、早治疗是延长NSCLC患者生存期的重要措施.
作者 康艳虹 马为
出处 《广东医学》 CAS CSCD 北大核心 2014年第4期524-527,共4页 Guangdong Medical Journal
  • 相关文献

参考文献14

  • 1FERLAY J,SHIN H R,BRAY F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.
  • 2陈万青,张思维,邹小农.中国肺癌发病死亡的估计和流行趋势研究[J].中国肺癌杂志,2010,13(5):488-493. 被引量:517
  • 3RIVERA M P,STOVER D E.Gender and lung cancer[J].Clin Chest Med,2004,25(2):391-400.
  • 4SAKURAI H,ASAMURA H,GOYA T,et al.Survival diffe-rences by gender for resected non-small cell lung cancer:a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Regi-stry study[J].J Thorac Oncol,2010,5(10):1594-1601.
  • 5NOVOTNY P,COLLIGAN R C,SZYDLO D W,et al.A pessimistic explanatory style is prognostic for poor lung cancer survival[J].J Thorac Oncol,2010,5(3):326-332.
  • 6HENSCHKE C I,YANKELEVITZ D F,LIBBY D M,et al.Survival of patients with stage Ⅰ lung cancer detected on CT screening[J].N Engl J Med,2006,355(17):1763-1771.
  • 7GORENSTEIN L A,SONETT J R.The surgical management of stage Ⅰ and stage Ⅱ lung cancer[J].Surg Oncol Clin N Am,2011,20(4):701-720.
  • 8FESINMEYER M D,GOULART B,BLOUGH D K,et al.Lung cancer histology,stage,treatment,and survival in American Indians and Alaska Natives and whites[J].Cancer,2010,116(20):4810-4816.
  • 9PFANNSCHMIDT J,DIENEMANN H.Surgical treatment of oligometastatic non-small cell lung cancer[J].Lung Cancer,2010,69(3):251-258.
  • 10DARLING G E,ALLEN M S,DECKER P A,et al.Randomized trial of mediastinal lymph node sampling versus complete lympha-denectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma:results of the American College of Surgery Oncology Group Z0030 Trial[J].J Thorac Cardiovasc Surg,2011,141(3):662-670.

二级参考文献173

  • 1张维森,江朝强,Lam T.Hing,Ho S.Yin,陈清,刘薇薇,何健民,曹民.接尘、吸烟者死亡危险度比较的前瞻性队列研究[J].中华流行病学杂志,2004,25(9):748-752. 被引量:19
  • 2张思维,陈万青,孔灵芝,李光琳,赵平.中国部分市县2003年恶性肿瘤发病年度报告[J].中国肿瘤,2007,16(7):494-507. 被引量:100
  • 3全国肿瘤防治研究办公室,全国肿瘤登记中心,卫生部疾病预防控制局.中国肿瘤登记年报(2004).北京:中国协和医科大学出版社,2008:10.
  • 4中华人民共和国卫生部.全国第三次死因回顾抽样调查报告.北京:中国协和医科大学出版社,2008:10.
  • 5陈万青,张思维,孔灵芝,李光琳,赵平.中国部分市县2003年恶性肿瘤死亡年度报告[J].中国肿瘤,2007,16(8):586-597. 被引量:21
  • 6Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002.
  • 7Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-132S, 2004.
  • 8Rosell R, Scagliotti G, Danenberg KD, et al Transcripts in pretreatment biopsies from a threearm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22:3548-3553, 2003.
  • 9Simon G, Sharma A, Li X, et al Feasibility and efficacy of molecular analy- sis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol25:2741-2746, 2007.
  • 10Tibaldi C, Giovannetti E, Vasile E, et al: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797-1803, 2008.

共引文献556

同被引文献72

  • 1叶斌,赖瑞楠,王升晔,张苏展.晚期肺癌患者预后因素分析[J].中国老年学杂志,2014,34(9):2327-2329. 被引量:9
  • 2王兴春.老年非小细胞肺癌患者化疗后细胞免疫功能的变化[J].中国老年学杂志,2014,34(7):1796-1797. 被引量:15
  • 3周从明,张西,李浩.GP和NP方案治疗晚期非小细胞肺癌的对比研究[J].西部医学,2007,19(4):538-540. 被引量:2
  • 4Jemal A,Bray F,Center MM,et al. Global cancer statistics[J].CA Cancer J Clin,2011,61 (2) :69-90.
  • 5Arriagada R,Dunant A,Pignon JP,et al. Long-term resultsof the international adjuvant lung cancer trial evaluatingadjuvant cisplatin -based chemotherapy in resected lungcancer[J], J Clin Oneol,2010,28(1) :35-42.
  • 6Ozkaya S, Findik S, Atici AG, et al. Cisplatin-based chemotherapy in elderly patients with advanced stage ( III B and IV) non-small cell lung cancer patients [ J ]. Neoplasma, 2011,58 ( 4 ) : 348 - 351.
  • 7Kaira K,Takahashi T, Murakami H,et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer [ J ]. Lung Cancer,2010,67( 1 ) : 120 -123.
  • 8Cho SH, Park LC, Ji JH, et al. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation[J]. Cancer Chemother Pharmacol,2012,70(2) :315 - 320.
  • 9Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyro- sine kinase inhibitors in patients with EGFR-mutated non-small- cell lung cancer:a meta-analysis of 13 randomized trims [ J ]. Clin Lung Cancer,2011,13 (2) : 107 - 114.
  • 10Lim SH, Lee JY, Sun JM, et al. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mu-tation in either exon 19 or 21 [ J ]. ] Thorac Oncol,2014,9 (4) : 506 -511.

引证文献6

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部